Refine by
Breast Cancer With Adjacent Normal Breast Suppliers & Manufacturers
67 companies found
based inLa Jolla, CALIFORNIA (USA)
Avelas is a clinical-stage drug-device company pioneering the field of fluorescence imaging for real-time cancer detection. Avelas is focused on the development and commercialization of pegloprastide (also referred to as “AVB-620”), a novel ...
Pegloprastide (AVB-620) is based on the science of activatable cell-penetrating peptides and is designed to deliver a fluorescent marker specifically to cancer cells to enable surgeons to identify cancerous tissue in real-time and thus, avoid repeat ...
based inMiami, FLORIDA (USA)
Veru is a biotechnology company focused on developing novel medicines for COVID-19, additional ARDS-related diseases, and for breast and prostate cancers. Veru is a Wisconsin corporation and is the successor to The Wisconsin Pharmacal Company, Inc. ...
based inWashington, DISTRICT OF COLUMBIA (USA)
TriStar is a Maryland LLC founded in 2003 with a business office in Washington DC. Our manufacturing, IHC and Molecular Lab is in Catania (Italy) and collaborating Medical institutes in Germany, Italy, UK & France TriStar has pioneered the use of ...
Molecular Data: Yes; Approx. # of Donors: 72; Follow Up Data: No; Cores per Donor: 2; Core Size: 1mm; Approx. # of Cores *: 144; TA number: TA3124; List of markers: CD3, CD4, CD8, CD20, CD68, CD163, FOXP3, PD1, PD-L1(22C3); Suitable for (IHC or ...
based inBristol, UNITED KINGDOM
At Micrima, we are transforming breast tissue analysis to empower earlier, more personalised breast cancer diagnosis. Our innovative Mi~Scan® technology uses safe, harmless radio waves and AI to measure breast tissue properties - quickly, safely, ...
Micrima are aiming to open up breast screening to all women. With breast cancer being the most common cancer in women of all ages globally, we believe that all women should be able to have breast screening. The current option for screening is ...
based inTeton Village, WYOMING (USA)
Environmental Health Trust (EHT) is a think tank that promotes a healthier environment through research, education, and policy. We are the only nonprofit organization in the world that carries out cutting-edge research on environmental health ...
based inAix-en-Provence, FRANCE
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a new generation ultrasound system, Aixplorer, with an UltraFast platform that can ...
based inShatin, CHINA
Time Medical (TM) is a leader in the medical diagnostic imaging industry with innovative and disruptive technology. TM develops advanced medical imaging systems including MRI, DR, and CT, as well as cost-effective solutions for emerging global ...
The EMMA 1.5T MRI is designed to offer breast imaging centers a new adjunctive tool to their current equipment options. Emma is a whole body MRI with dedicated breast coils for exclusive high-quality imaging. In collaboration with leading breast ...
based inPhiladelphia, PENNSYLVANIA (USA)
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...
based inChicago, ILLINOIS (USA)
Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we ...
Providing risk-assessment for hereditary cancer syndromes for patients and their families. xG+ (extended hereditary cancers): Covers genes associated with multiple hereditary cancer types, including common hereditary cancers (breast, ovarian, ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
The mechanism of action of Bria-IMT™/Bria-OTS™ is currently under investigation. We believe that Bria-IMT™/Bria-OTS™, activates the patient’s immune system to recognize tumor cells and destroy them. We hypothesize that ...
based inNangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
based inPlymouth, MASSACHUSETTS (USA)
We started Medical Monofilament in 1999 in order to produce the best sensory testing monofilament available. Our goal was and still is to help decrease the incidence of diabetic foot ulcerations and amputations for diabetic patients at risk. For ...
based inRedwood City, CALIFORNIA (USA)
Auris Health was acquired by Ethicon, part of the Johnson & Johnson Medical Devices Companies, in 2019. Over the past 50 years, the introduction of new technologies has ushered in the era of minimally invasive techniques and procedures. Despite ...
based inPozuelo de Alarcón, SPAIN
We are a specialized pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products. Our operations encompass the marketing of both our own and licensed products and the provision of services, such ...
based inGoerlitz, GERMANY
Sysmex Partec is the newly formed collaboration between Partec, a worldwide leading pioneer, developer and manufacturer of flow cytometry systems and Sysmex Corporation, a leading international supplier of in vitro diagnostic products. Sysmex Partec ...
Highly sensitive down to 0.06 % MAF, Able to detect 6 MM with 95 % confidence across all mutations (absolute quantification), High flexibility of between 2-16 samples/run, Fast TAT (2 days), Convenient software. Plasma-SeqSensei (PSS) BC RUO Kit ...
based inSyracuse, NEW YORK (USA)
Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet technology is a ...
based inBeverly, MASSACHUSETTS (USA)
Cellanyx is a growth stage emerging biotech advancing proprietary phenotypic (appearance and dynamics) biomarker tests based on Machine Vision and AI-driven analysis of live single tumor cells to improve risk-stratification and shared clinical ...
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no ...
based inOrlando, FLORIDA (USA)
Imaging Diagnostic Systems, Inc. (IDSI) is a medical device company headquartered in Florida, specializing in the research, development, and marketing of innovative cancer detection systems. Their flagship product, the CTLM system (Computed ...
Computed Tomography Laser Mammography (CTLM) is an innovative imaging method focused on visualizing blood distribution within the breast, helpful for identifying breast abnormalities. This technology offers potential advantages in detecting ...
based inBreitenfurt, AUSTRIA
Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology ...
Lead candidate OQR200 is a new candidate against HER2/neu, the by far best characterized and clinically validated target to treat breast cancer indications. A reversible induction of HER2/neu specific antibodies has been demonstrated. In vitro, the ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of ...